- Conditions
- Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
- Interventions
- Cohort study
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,948
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- STI-9199, Placebo
- Drug
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Covid 19
- Interventions
- Not listed
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Conjunctivitis, SARS-CoV-2, COVID-19, Ocular Infection, Viral, Ocular Inflammation
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Asthma
- Interventions
- insurance navigation
- Behavioral
- Lead sponsor
- Harvard Pilgrim Health Care
- Other
- Eligibility
- 4 Years to 64 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Wellesley, Massachusetts
- Conditions
- COVID-19
- Interventions
- Aprepitant injectable emulsion, Saline Placebo
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Sheffield, Alabama • Orange, California • New Haven, Connecticut
- Conditions
- COVID-19
- Interventions
- RD-X19, Sham
- Device
- Lead sponsor
- EmitBio Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 48
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 42 more
- Conditions
- Neuro-PASC, Long COVID
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Mountain Home, Tennessee
- Conditions
- COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Lucinactant
- Drug
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- La Jolla, California • San Diego, California • Augusta, Georgia + 3 more
- Conditions
- Covid19
- Interventions
- Disulfiram, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Fresno, California • San Francisco, California
- Conditions
- COVID-19
- Interventions
- IBI314, Placebo
- Biological · Other
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 19
- States / cities
- Anaheim, California • Long Beach, California • San Diego, California + 12 more
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Interventions
- BNT162b2, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 726 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more
- Conditions
- COVID-19
- Interventions
- EDP-235, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Lomita, California • Los Angeles, California • Aventura, Florida + 10 more
- Conditions
- COVID-19, Lyme Disease, COVID-19 Vaccine
- Interventions
- Cross sectional survey
- Other
- Lead sponsor
- Dr. Daniel Cameron & Associates
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 2,000 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Mount Kisco, New York
- Conditions
- COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
- Interventions
- Gabapentin gelatin capsules 300mg, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection
- Interventions
- Convalescent Plasma
- Biological
- Lead sponsor
- Jonathan Gerber
- Other
- Eligibility
- 12 Years and older
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- COVID-19
- Interventions
- Previously admitted COVID-19 patients in intensive care units
- Other
- Lead sponsor
- The University of Queensland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- COVID-19, Acute Kidney Injury, Sepsis
- Interventions
- SBI-101
- Biological
- Lead sponsor
- Sentien Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico • Charleston, South Carolina
- Conditions
- COVID-19
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Fairfax, Virginia
- Conditions
- COVID-19
- Interventions
- Brilacidin, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Innovation Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Winfield, Illinois • Toledo, Ohio
- Conditions
- Long Covid-19, PASC Post Acute Sequelae of COVID 19, Brain Fog, Fatigue
- Interventions
- rTMS
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Interventions
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 4,338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more